RIPK2 and hematologic disorder: A comprehensive evaluation of kinase-binding inhibitory activity assay demonstrated that only four off-target kinases, namely TEC, BMX, HUNK, and RIPK2, were inhibited by tirabrutinib, while there are no significant reports to indicate the involvement of these four kinases in anti-tumor effects in hematological malignancies.